Separately, analysts at CL King upgraded shares of Steris from a “sell” rating to a “neutral” rating in a research note to investors on Tuesday, March 13rd.
Steris traded up 0.17% on Wednesday, hitting $30.06. Steris has a 52-week low of $27.08 and a 52-week high of $36.76. The company has a market cap of $1.734 billion and a price-to-earnings ratio of 12.99.
Steris last posted its quarterly earnings results on Tuesday, May 8th. The company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by $0.01. The company’s revenue for the quarter was down .8% on a year-over-year basis. Analysts expect that Steris will post $0.54 EPS next quarter.
STERIS Corporation is a provider of infection prevention and surgical products and services, focused primarily on the critical markets of healthcare, pharmaceutical and research.